Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hisamitsu Ordered to Suspend Biz over Salonpas OTC Data Tampering
August 13, 2021
- Lenvima Plus Keytruda Approved for RCC in US
August 13, 2021
- Reps’ Face-to-Face Meetings Remain Flat YOY in June; Growth Seen across All Channels from May: Intage
August 13, 2021
- Morimoto Pharma Aims at Commercial Production of Freeze-Dried Vaccine in FY2022
August 12, 2021
- Japan Ethical Drug Sales Rise 2.1% in June: Crecon
August 12, 2021
- Ex-HBS Dean Nitin Nohria Tapped as Board Chair at Rakuten Medical
August 12, 2021
- Cost-Effectiveness Simulation Model Developed for Type 2 Diabetes: Novo
August 12, 2021
- Orizuru Therapeutics Boots Up to Take Over iPSC Assets from T-CiRA, Eyes IPO in 2026
August 11, 2021
- Santen Snags EMEA Rights to Sydnexis’ Myopia Drug
August 11, 2021
- Daiichi Sankyo’s Enhertu Beats Kadcyla in 2nd-Line Breast Cancer
August 11, 2021
- Meiji Distributing AstraZeneca’s COVID-19 Vaccine in Japan
August 11, 2021
- Healios Bolsters Capital Alliance with Athersys, Gets Manufacturing License for Cell Therapy Product
August 10, 2021
- Vitrakvi Oral Solution Now Available in Japan: Bayer
August 10, 2021
- Pfizer Japan Announces Shipment Curbs, Stockouts for 9 Products in Knock-On Effect
August 10, 2021
- Otsuka’s 4 Global Brands Likely to Hit 480 Billion Yen, 2 Years Earlier
August 10, 2021
- HIF-PH Drugs’ Sluggish Q1 Sales Signal Tepid Uptake as Side Effect Concerns Weigh
August 10, 2021
- Foreign Drug Makers Scrapping Sales Offices as Sanofi Follows GSK, Novartis, AZ
August 6, 2021
- Kissei Sublicenses Fostamatinib to Chinese Firm
August 6, 2021
- Mitsubishi Tanabe’s NMOSD Drug Approved in South Korea
August 6, 2021
- Opdivo Snatches Back Top Spot in Japan Drug Ranking in July: Encise
August 6, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…